|
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
In this trial, monoclonal anti-Disialoganglioside GD2 (GD2) antibody ch14.18/CHO will be assessed for the treatment of patients with relapsed or refractory neuroblastoma. The antibody is used as a single agent applied in a new treatment schedule associated with less side effects.
100 项与 Children'S Cancer Research Institute 相关的临床结果
0 项与 Children'S Cancer Research Institute 相关的专利(医药)
100 项与 Children'S Cancer Research Institute 相关的药物交易
100 项与 Children'S Cancer Research Institute 相关的转化医学